

DRUG DELIVERY PLATFORM INNOVATOR

Lexaria Bioscience Corp's. (Nasdaq: LEXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. The Company's technology can be applied to many different ingestible product formats, including, oral suspensions, tablets, capsules, and more. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also planned for evaluation for anti-virals, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and more. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.

Lexaria Bioscience Corp. (Nasdaq: LEXX)

Disruptive, patented technology - fast acting, less expensive & more effective oral drug delivery:


- **Antivirals** (COVID-19, infectious diseases); **Oral Nicotine**; **NSAIDs** (Ibuprofen, Aspirin); **Cannabinoids**; **Fat-Soluble Vitamins** (A,D,E,K); **PDE5 Inhibitors** (Viagra, Cialis); **Hormones** (Estrogen, Testosterone)
- Close collaboration with largest R&D organization in Canada, the National Research Council, since January 2017
- Programs commenced to evaluate delivery effectiveness with cannabidiol (CBD) for hypertension and with antiviral therapies for SARS (incl. COVID-19) and other infectious diseases.
- Oral nicotine formats under investigation to disrupt \$990-billion global nicotine market

DehydraTECH™

- Patented formulation and dehydration processing method changes how the body detects and absorbs drugs orally
- Faster onset/offset and higher bioavailability in capsules, foods, liquids, mixable powders, etc.
- 18 patents granted (>60 pending) covering method-of-use, composition-of-matter and medical treatment claims



Patented DehydraTECH Process (Simplified)



Recent Highlights

- Uplisted to Nasdaq Capital Market and closed \$11 million upsized public offering
- Expanded R&D Program to address US\$28-billion hypertension market with addition of two human clinical studies, bringing total to three human clinical and two animal studies
- Expanded COVID-19 drug research program utilizing proprietary DehydraTECH™
- Lexaria's patented technology significantly enhances oral delivery of antiviral drugs
- Lexaria sells non-pharmaceutical THC-related assets for CDN\$3.85M - approx. US\$2.85M

PRICE	52-WK. RANGE	AVG. VOL	SHARES OUTSTANDING	MARKET CAP	INSIDER OWNERSHIP
\$6.31 (3/11/21)	\$3.97-\$9.46	337K	5.1M	\$32.2M	12.28%

Key Growth Drivers

- The global controlled release drug delivery market is expected to reach **\$69.8B** in 2027, and the global drug delivery system market is estimated to reach **\$900B** by 2025, according to Grand View Research and Transparency Market Research. Lexaria plans to disrupt the Global Tobacco Market forecasted to reach **\$1.08 Trillion** in 2027 by Grandview Research;
- Investigation planned or underway with CBD for hypertension, antivirals for COVID 19 and other infectious diseases, and for nicotine;
- Rapidly growing revenue generation for DehydraTECH enabled CBD powders;
- Disruptive drug delivery technology with multiple opportunities for success in antivirals, nicotine, cannabinoids, hormones, other;
- Established revenue-generating commercial partnerships for other APIs of interest; additional DehydraTECH transactions expected through 2021;
- Uplisted to Nasdaq in January 2021

Lexaria Nicotine LLC (Majority-Owned)

- Oral nicotine products to disrupt the \$990 billion global nicotine market
- Altria Group international license rights for undisclosed royalty
- R&D agreement with British American Tobacco
- Also in discussions with other global tobacco and pharmaceutical companies to use DehydraTECH for oral nicotine products internationally



Lexaria Pharmaceutical Corp. (Wholly-Owned)

- Programs commenced to prove delivery effectiveness in antiviral therapies for SARS diseases (incl. COVID-19) and other infectious diseases



Lexaria Hemp Corp. (Wholly-Owned)

- Clinically proved to increase rate and extent of orally ingested CBD - (<https://www.ncbi.nlm.nih.gov/pubmed/31512143>)
- FDA has begun to engage Congress on rulemaking for CBD dietary supplement commercialization in the U.S.



MANAGEMENT



Chris Bunka, Chairman & CEO

- Launched several successful private and public companies since the late 1980's
- Extensive experience in the capital markets, corporate governance, M&A and finance
- Named inventor on multiple patent innovations



John Docherty, M.Sc., President & Director

- Specialist in development of drug delivery technologies
- Former President and COO of Helix BioPharma Corp. (TSX: HBP)
- Named inventor on multiple issued and pending patents
- Pharmacologist and toxicologist

Disclaimer: This fact sheet includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, evaluation of medical marijuana projects, alternative health projects or products, and cannabidiol-fortified products or services for participation and/or financing, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements including, without limitation, foreign exchange and other financial markets; changes of the interest rates on borrowings; whether or not the Company will be successful in executing its business plan in whole or in part; hedging activities; changes in commodity prices; changes in the marketing or capital project expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Lexaria Corp. operates. These and other risks and uncertainties are more fully described in our periodic reports and other disclosure documents filed by Lexaria Corp. from time to time with regulatory authorities available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov, and the reader is encouraged to review these documents. Planned dates stated herein are estimates only, based on best information available. Dates are not assured and are subject to revision without notice. The Company assumes no obligation, except as required by law, to update any forward-looking statement, whether as a result of new information, future events or otherwise. This fact sheet is not an offer to sell or a solicitation of an offer to buy securities of Lexaria Bioscience Corp. It is a short summary of certain information for introductory purposes only and is not to be relied upon for investment purposes. No statement within has been evaluated by the Food and Drug Administration, and no product or service is intended to diagnose, treat, cure or prevent any disease.